Find the Right GRC Solution

Search and compare GRC technology built for the problems you’re trying to solve

DNB Updates Factsheet on Declarations of No-Objection for Dutch Insurer Capital Actions & IPOs

DNB Updates Factsheet on Declarations of No-Objection for Dutch Insurer Capital Actions & IPOs

By
Regulatory data powered by Corlytics
De Nederlandsche Bank updated its factsheet on Section 3:97 of the Wft, which requires Dutch-domiciled insurers to obtain a declaration of no-objection (DNO) b…
🔒
Cancel anytime
Full archive access
Custom alerts
Key Takeaways
  • De Nederlandsche Bank updated its factsheet on Section 3:97 of the Wft, which requires Dutch-domiciled insurers to obtain a declaration of no-objection (DNO) before reducing own funds under specified conditions or seeking admission of control-bearing securities to a regulated market.
  • Compliance teams should confirm that capital management and corporate finance processes include DNO checkpoints, particularly given the IPO-related DNO obligation in force since 1 January 2025.
Deep Dive

De Nederlandsche Bank updated its factsheet on Section 3:97 of the Wft, which requires Dutch-domiciled insurers to obtain a declaration of no-objection (DNO) before reducing own funds under specified conditions or seeking admission of control-bearing securities to a regulated market. Compliance teams should confirm that capital management and corporate finance processes include DNO checkpoints, particularly given the IPO-related DNO obligation in force since 1 January 2025.

The factsheet, last updated on 22 September 2026, restates two acts that require prior DNB approval for insurers with a registered office in the Netherlands. The first, under Section 3:97(a), covers reductions of own funds through capital repayments, reserve distributions, or dividends. This DNO requirement applies only if the insurer does not meet the solvency capital requirement (SCR) when making the payment, or is expected to fall short of it within the next twelve months. The second, under Section 3:97(b), covers changes to capital structure through a request for admission to trading on a regulated market of shares or other securities that carry control.

The most recent amendment is the IPO-related DNO obligation, effective 1 January 2025. The update does not appear to introduce new substantive requirements. It consolidates and clarifies existing obligations, so teams should treat it as a reference point for validating current procedures. DNB assesses applications under Section 3:101 of the Wft, focusing on solvency, sound and prudent business operations, and whether the act might or would lead to an undesirable development of the financial sector.

For compliance teams, the forward-looking twelve-month test is the main operational challenge. Dividend and distribution decisions must be supported by solvency projections, stress testing, and capital planning that can show whether the SCR is at risk. Where projections indicate a possible breach, the DNO becomes a gating item. Making a distribution without a required DNO exposes the insurer to supervisory enforcement and reputational harm, and may raise governance concerns for management.

Recommended actions:

(1) map dividend, capital repayment, and reserve distribution workflows to Section 3:97(a) triggers and document the forward-looking SCR assessment;

(2) add a DNO checkpoint to IPO and listing readiness plans, including for group structures where a Dutch insurer is affected;

(3) review the DNB application form, fee schedule, and processing time frames to build realistic lead times into transaction timetables;

(4) engage early with DNB where capital positions are close to thresholds; and

(5) brief the board, the actuarial function, and legal counsel on the criteria and escalation paths. Teams should also check related DNO regimes, such as shareholdings under Section 3:95 and group company DNOs, for overlapping requirements.

Overall impact is moderate. The rules are narrow in scope, but the consequences of non-compliance are significant for capital-constrained insurers and those planning market listings.

Source: De Nederlandsche Bank

Oops! Something went wrong